NCT07006298

Brief Summary

Background: The GOLDENEYE study is an international, multicenter, prospective observational investigation designed to compare the outcomes of various management strategies for acute cholecystitis in patients aged 70 years and older. This research is driven by the increasing prevalence of gallstones and biliary tract diseases in the elderly, alongside a recognition that the burden of comorbidity in this population may necessitate tailored treatment approaches to optimize outcomes. Patients and Methods: The primary aims of the study are to evaluate the efficacy of different treatments -supportive care, percutaneous gallbladder drainage, early or delayed cholecystectomy, and EUS-guided gallbladder drainage- on patient-centric outcomes, including one-year additional treatment modalities, hospital readmissions, outpatient encounters, quality of life, and survival rates. The study adopts a robust design incorporating propensity score matching analysis to account for the non-randomized allocation of treatment modalities, thereby minimizing selection bias and enhancing the comparability of treatment groups. Inclusion criteria are centered on patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines, while key exclusion criteria include prior episodes of cholecystitis or pancreatitis, terminal illness, and concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy. Data collection will leverage the REDCap platform for systematic and secure data management, facilitating real-time data entry and monitoring across participating centers. Discussion: This comprehensive approach ensures the integrity and reliability of data collected on demographics, gender, clinical outcomes, and quality of life measures. Through its innovative design and methodology, the GOLDENEYE study aims to generate evidence-based insights that will significantly influence the management of acute cholecystitis in the elderly, ultimately improving patient outcomes and healthcare practices in this growing demographic population.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
376

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started May 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
May 2025May 2027

First Submitted

Initial submission to the registry

May 14, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

May 15, 2025

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 5, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2027

Last Updated

June 8, 2025

Status Verified

May 1, 2025

Enrollment Period

2 years

First QC Date

May 14, 2025

Last Update Submit

June 6, 2025

Conditions

Keywords

laparoscopic cholecystectomyConservative TreatmentdrainageEndosonographyPropensity ScoreRetrospective Studies

Outcome Measures

Primary Outcomes (1)

  • 1 year additional procedures, hospital readmissions or outpatient visits

    Percentage of patients requiring any additional procedure, hospital readmission or outpatient visit during the first year.

    1 year

Secondary Outcomes (2)

  • 1-year health-related quality of life

    1 year

  • 1-year overall survival

    1 year

Study Arms (4)

Supportive care

Patients that received antibiotics only

Cholecystectomy

Patients that undergo early or delayed cholecystectomy

percutaneous gallbladder drainage

Patients that undergo percutaneous gallbladder drainage

EUS-guided gallbladder drainage

Patients that undergo EUS-guided gallbladder drainage

Eligibility Criteria

Age70 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines

You may qualify if:

  • patients ≥70 years
  • diagnosed with acute cholecystitis, as per the Tokyo guidelines

You may not qualify if:

  • prior episodes of cholecystitis or pancreatitis
  • terminal illness
  • concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)

Alicante, Alicante, 03010, Spain

RECRUITING

Related Publications (1)

  • Lluis N, Perez-Brotons S, de Castro I, Martinez B, Aparicio JR, Zapater P, Lluis F, de-Madaria E. One-year outcomes by index treatment in older patients with acute cholecystitis. Protocol of the international, prospective, observational GOLDENEYE study. Cir Esp (Engl Ed). 2025 Dec 23:800282. doi: 10.1016/j.cireng.2025.800282. Online ahead of print.

Related Links

MeSH Terms

Conditions

Cholecystitis, Acute

Condition Hierarchy (Ancestors)

CholecystitisGallbladder DiseasesBiliary Tract DiseasesDigestive System Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

May 14, 2025

First Posted

June 5, 2025

Study Start

May 15, 2025

Primary Completion (Estimated)

May 15, 2027

Study Completion (Estimated)

May 15, 2027

Last Updated

June 8, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

The Steering Committee and statistical advisors will have access to the final dataset. Members of the GOLDENEYE study that recruited patients may claim access to the final dataset to perform ancillary studies; the Steering Committee will study these proposals. Any data required to support the protocol can be supplied on request.

Locations